[1]

Draman MS, Zhang L, Dayan C, Ludgate M. 2021. Orbital signaling in Graves' orbitopathy. Frontiers in Endocrinology 12:739994

doi: 10.3389/fendo.2021.739994
[2]

Wiersinga WM, Eckstein AK, Žarković M. 2025. Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management. The Lancet Diabetes & Endocrinol 13(7):600−614

doi: 10.1016/S2213-8587(25)00066-X
[3]

Wang CJ, Gao T, Zhang HN, Xie JJ, Gao Q, et al. 2023. Medial-inferior wall orbital decompression combined with fat decompression in the treatment of moderate-to-severe thyroid associated ophthalmopathy. Yan Ke Xue Bao/Eye Science 38(5):381−386

doi: 10.12419/j.issn.1000-4432.2023.05.03
[4]

Bahn RS. 2010. Graves' ophthalmopathy. New England Journal of Medicine 362(8):726−738

doi: 10.1056/NEJMra0905750
[5]

Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, et al. 2021. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. European Journal of Endocrinology 185(4):G43−G67

doi: 10.1530/EJE-21-0479
[6]

Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, et al. 2022. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology 129(4):438−449

doi: 10.1016/j.ophtha.2021.10.017
[7]

Ko J, Kim YJ, Choi SH, Lee CS, Yoon JS. 2023. Yes-associated protein mediates the transition from inflammation to fibrosis in Graves' orbitopathy. Thyroid 33(12):1465−1475

doi: 10.1089/thy.2023.0309
[8]

Dwivedi SN, Kalaria T, Buch H. 2023. Thyroid autoantibodies. Journal of Clinical Pathology 76(1):19−28

doi: 10.1136/jcp-2022-208290
[9]

Smith TJ, Janssen JAMJL. 2019. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocrine Reviews 40(1):236−267

doi: 10.1210/er.2018-00066
[10]

Zhang P, Zhu H. 2022. Cytokines in thyroid-associated ophthalmopathy. Journal of Immunology Research 2022:2528046

doi: 10.1155/2022/2528046
[11]

Chiu HI, Wu SB, Tsai CC. 2024. The role of fibrogenesis and extracellular matrix proteins in the pathogenesis of Graves' ophthalmopathy. International Journal of Molecular Sciences 25(6):3288

doi: 10.3390/ijms25063288
[12]

Kim MS, Choi SH, Park HY, Jang SY, Ko J, et al. 2025. Role of SerpinA3 in the pathogenesis of Graves' orbitopathy in orbital fibroblasts. Investigative Ophthalmology & Visual Science 66(4):20

doi: 10.1167/iovs.66.4.20
[13]

Niu T, Wang L, Deng J, Shi Y, Liu Y, et al. 2025. Combining biomarkers to predict the disease activity of Graves' ophthalmopathy: a combinatory model of the NLR, TRAb and FT4. Frontiers in Endocrinology 16:1546211

doi: 10.3389/fendo.2025.1546211
[14]

Kulbay M, Tanya SM, Tuli N, Dahoud J, Dahoud A, et al. 2024. A comprehensive review of thyroid eye disease pathogenesis: from immune dysregulations to novel diagnostic and therapeutic approaches. International Journal of Molecular Sciences 25(21):11628

doi: 10.3390/ijms252111628
[15]

Antonelli A, Ferrari SM, Corrado A, Franceschini SS, Gelmini S, et al. 2014. Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ. Autoimmunity Reviews 13(11):1160−1166

doi: 10.1016/j.autrev.2014.08.025
[16]

Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, et al. 2006. Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. The Journal of Clinical Endocrinology & Metabolism 91(2):614−620

doi: 10.1210/jc.2005-1689
[17]

Kim SE, Yoon JS, Kim KH, Lee SY. 2012. Increased serum interleukin-17 in Graves' ophthalmopathy. Graefe’s Archive for Clinical and Experimental Ophthalmology 250(10):1521−1526

doi: 10.1007/s00417-012-2092-7
[18]

Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, et al. 2018. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. American Journal of Ophthalmology 195:181−190

doi: 10.1016/j.ajo.2018.07.038
[19]

Sun A, Wang X, Qu J, Wu Y. 2025. The Efficacy and safety of intravenous tocilizumab to treat Graves' ophthalmopathy: a systematic review and single-arm meta-analysis. The Journal of Clinical Endocrinology & Metabolism 110(3):e886−e896

doi: 10.1210/clinem/dgae711
[20]

Chen J, Cao X, Chen X, Li Z, Chen X, et al. 2024. Causal relationship between central corneal thickness and open-angle glaucoma: evidence from Mendelian randomization. Experimental Eye Research 246:110000

doi: 10.1016/j.exer.2024.110000
[21]

Thanassoulis G, O'Donnell CJ. 2009. Mendelian randomization: nature's randomized trial in the post-genome era. JAMA 301(22):2386−2388

doi: 10.1001/jama.2009.812
[22]

Emdin CA, Khera AV, Kathiresan S. 2017. Mendelian randomization. JAMA 318(19):1925−1926

doi: 10.1001/jama.2017.17219
[23]

Zhu Y, Chen J, Wen Y, Li Z, Ling Y, et al. 2025. Association of COVID-19 susceptibility and severity with primary angle-closure glaucoma. Ophthalmic Epidemiology 32(6):736−743

doi: 10.1080/09286586.2025.2547274
[24]

Yuan Y, Liang X, Kang S, Liu Y. 2025. The mediation of circulating inflammatory proteins in the causal pathway from immune cells to osteoarthritis. Journal of Orthopaedic Surgery and Research 20(1):939

doi: 10.1186/s13018-025-06374-y
[25]

Carter AR, Sanderson E, Hammerton G, Richmond RC, Davey Smith G, et al. 2021. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. European Journal of Epidemiology 36(5):465−478

doi: 10.1007/s10654-021-00757-1
[26]

Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, et al. 2023. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613(7944):508−518

doi: 10.1038/s41586-022-05473-8
[27]

Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman ÅK, et al. 2023. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nature Immunology 24(9):1540−1551

doi: 10.1038/s41590-023-01588-w
[28]

Verma A, Huffman JE, Rodriguez A, Conery M, Liu M, et al. 2024. Diversity and scale: genetic architecture of 2068 traits in the VA million veteran program. Science 385(6706):eadj1182

doi: 10.1126/science.adj1182
[29]

Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, et al. 2018. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nature Genetics 50(9):1335−1341

doi: 10.1038/s41588-018-0184-y
[30]

Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. 2015. A global reference for human genetic variation. Nature 526:68−74

doi: 10.1038/nature15393
[31]

Chen J, Chen X, Cao X, Zhuo X, Wen Y, Ye G, et al. 2025. Associations between diabetic retinopathy and frailty: insights from the national health and nutrition examination survey and Mendelian randomization. Translational Vision Science & Technology 14(2):2

doi: 10.1167/tvst.14.2.2
[32]

Hemani G, Tilling K, Davey Smith G. 2017. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genetics 13(11):e1007081

doi: 10.1371/journal.pgen.1007081
[33]

Liu J, Rutten-Jacobs L, Liu M, Markus HS, Traylor M. 2018. Causal impact of type 2 diabetes mellitus on cerebral small vessel disease: a Mendelian randomization analysis. Stroke 49(6):1325−1331

doi: 10.1161/STROKEAHA.117.020536
[34]

Lv X, Hu Z, Liang F, Liu S, Gong H, et al. 2023. Causal relationship between ischemic stroke and its subtypes and frozen shoulder: a two-sample Mendelian randomization analysis. Frontiers in Neurology 14:1178051

doi: 10.3389/fneur.2023.1178051
[35]

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. The American Journal of Human Genetics 81(3):559−575

doi: 10.1086/519795
[36]

Burgess S, Butterworth A, Thompson SG. 2013. Mendelian randomization analysis with multiple genetic variants using summarized data. Genetic Epidemiology 37(7):658−665

doi: 10.1002/gepi.21758
[37]

Bowden J, Holmes MV. 2019. Meta-analysis and Mendelian randomization: a review. Research Synthesis Methods 10(4):486−496

doi: 10.1002/jrsm.1346
[38]

Bowden J, Spiller W, Del Greco M F, Sheehan N, Thompson J, et al. 2018. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. International Journal of Epidemiology 47(4):1264−1278

doi: 10.1093/ije/dyy101
[39]

Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, et al. 2010. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Research 38:W214−W220

doi: 10.1093/nar/gkq537
[40]

Metcalfe R, Jordan N, Watson P, Gullu S, Wiltshire M, et al. 2002. Demonstration of immunoglobulin G, A, and E autoantibodies to the human thyrotropin receptor using flow cytometry. The Journal of Clinical Endocrinology & Metabolism 87(4):1754−1761

doi: 10.1210/jcem.87.4.8411
[41]

George A, Diana T, Längericht J, Kahaly GJ. 2021. Stimulatory thyrotropin receptor antibodies are a biomarker for Graves' orbitopathy. Frontiers in Endocrinology 11:629925

doi: 10.3389/fendo.2020.629925
[42]

Sarić Matutinović M, Diana T, Nedeljković Beleslin B, Ćirić J, Žarković M, et al. 2022. Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy. Journal of Endocrinological Investigation 45(1):189−197

doi: 10.1007/s40618-021-01652-y
[43]

Morshed SA, Ma R, Latif R, Davies TF. 2022. Mechanisms in Graves eye disease: apoptosis as the end point of insulin-like growth factor 1 receptor inhibition. Thyroid 32(4):429−439

doi: 10.1089/thy.2021.0176
[44]

Scarselli M, Donaldson JG. 2009. Constitutive internalization of G protein-coupled receptors and G proteins via clathrin-independent endocytosis. Journal of Biological Chemistry 284(6):3577−3585

doi: 10.1074/jbc.M806819200
[45]

Szukiewicz D. 2024. CX3CL1 (Fractalkine)-CX3CR1 axis in inflammation-induced angiogenesis and tumorigenesis. International Journal of Molecular Sciences 25(9):4679

doi: 10.3390/ijms25094679
[46]

Conroy MJ, Lysaght J. 2020. CX3CL1 signaling in the tumor microenvironment. In Tumor Microenvironment, ed. Birbrair A. Cham: Springer. pp.1−12 doi: 10.1007/978-3-030-36667-4_1
[47]

Miller AF, Falke JJ. 2004. Chemotaxis receptors and signaling. Advances in Protein Chemistry 68:393−444

doi: 10.1016/S0065-3233(04)68011-9
[48]

Wojdasiewicz P, Poniatowski ŁA, Kotela A, Deszczyński J, Kotela I, et al. 2014. The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis. Archivum Immunologiae et Therapiae Experimentalis 62(5):395−403

doi: 10.1007/s00005-014-0275-0
[49]

Johnston B, Butcher EC. 2002. Chemokines in rapid leukocyte adhesion triggering and migration. Seminars in Immunology 14(2):83−92

doi: 10.1006/smim.2001.0345
[50]

Mortier A, Van Damme J, Proost P. 2012. Overview of the mechanisms regulating chemokine activity and availability. Immunology Letters 145(1−2):2−9

doi: 10.1016/j.imlet.2012.04.015
[51]

Richmond A. 2011. Chemokine research moves on. Experimental Cell Research 317(5):553−555

doi: 10.1016/j.yexcr.2011.01.016
[52]

Zlotnik A, Yoshie O. 2012. The chemokine superfamily revisited. Immunity 36(5):705−716

doi: 10.1016/j.immuni.2012.05.008
[53]

Fang S, Lu Y, Huang Y, Zhou H, Fan X. 2021. Mechanisms that underly T cell immunity in Graves' orbitopathy. Frontiers in Endocrinology 12:648732

doi: 10.3389/fendo.2021.648732
[54]

Fallahi P, Ferrari SM, Ragusa F, Ruffilli I, Elia G, et al. 2020. Th1 chemokines in autoimmune endocrine disorders. The Journal of Clinical Endocrinology & Metabolism 105(4):1046−1060

doi: 10.1210/clinem/dgz289
[55]

Dong QY, Li SJ, Gao GQ, Liu XM, Li WX, et al. 2011. Short-term effect of radioactive iodine therapy on CXCL-10 production in Graves' disease. Clinical and Investigative Medicine 34(5):E262−E266

doi: 10.25011/cim.v34i5.15668
[56]

Ferrari SM, Ruffilli I, Elia G, Ragusa F, Paparo SR, et al. 2019. Chemokines in hyperthyroidism. Journal of Clinical & Translational Endocrinology 16:100196

doi: 10.1016/j.jcte.2019.100196
[57]

Smit MJ, Verdijk P, van der Raaij-Helmer EMH, Navis M, Hensbergen PJ, et al. 2003. CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C–dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. Blood 102(6):1959−1965

doi: 10.1182/blood-2002-12-3945
[58]

Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, et al. 2018. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – a target for novel cancer therapy. Treatment Reviews 63:40−47

doi: 10.1016/j.ctrv.2017.11.007
[59]

Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, et al. 2014. Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmunity Reviews 13(3):272−280

doi: 10.1016/j.autrev.2013.10.010
[60]

Liu C, Papewalis C, Domberg J, Scherbaum W, Schott M. 2008. Chemokines and autoimmune thyroid diseases. Hormone and Metabolic Research 40(6):361−368

doi: 10.1055/s-2008-1073153